Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PKN605 in atrial fibrillation to reduce atrial fibrillation burden
CTR20254349Phase 2Active
- Sponsor
- Novartis
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PKN605 in Atrial fibrillation (AFib), sponsored by Novartis. Started Jan 2026; status: active.
02
Drugs
PKN605
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on CTR20254349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254349.